University of Washington



CURRICULUM VITAE

Ronald L. Gibson, Jr., M.D., Ph.D. March 2009

1. Education

Undergraduate: 1972-75 University of Washington, Seattle, Washington - Major field of Biology, B.S.

Graduate: 1976-82 Washington University Schools of Medicine and Arts & Sciences, St. Louis, Missouri - M.D. and Ph.D.

Doctoral Thesis: The role of oligosaccharide chains in the maturation and physical properties of the G protein of vesicular stomatitis virus

2. Postgraduate Training

Internship: 1982-83 Pediatrics, University of Washington School of Medicine, Seattle, Washington

Residency: 1983-85 Pediatrics, University of Washington School of Medicine, Seattle, Washington

1985 Assistant Chief Pediatric Resident, University of

Washington School of Medicine, Seattle, Washington

Fellowship: 1985-88 Pediatric Pulmonology, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington

3. Faculty Positions Held

1988-1994 Assistant Professor, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington

1991-1997 Research Affiliate, Child Development and Mental Retardation Center, University of Washington, Seattle, Washington

1994-2003 Associate Professor, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington

2003-present Professor, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington

4. Hospital Positions Held

1988-present Attending Physician, Seattle Children's Hospital, Seattle, Washington

1988-present Consultant, University of Washington Medical Center, Seattle, Washington

1994-99 Consultant, Swedish Hospital & Medical Center Special Care Nursery, Seattle, Washington

5. Honors and Awards

1975 B.S. summa cum laude in Biology, University of Washington

1975 Phi Beta Kappa, University of Washington, Seattle, Washington

1976-82 Medical Scientist Training Grant from the National Institutes of Health, Washington University School of Medicine, St. Louis, Missouri

1977 Richard S. Brookings Medical Prize, Washington University School of Medicine, St. Louis, Missouri

1982 Alexander Berg Prize in Microbiology, Washington University School of Medicine, St. Louis, Missouri

1982 Alpha Omega Alpha (AOA), Washington University School of Medicine, St. Louis, Missouri

1991 Outstanding Teacher Award, University of Washington School of Medicine, Pediatric Residency Training Program

1997. Stanley Stamm Role Model Award in Medicine (for conscientious teaching and patient care), University of Washington School of Medicine, Pediatric Residency Training Program

1997 Society for Pediatric Research, Elected Member

1999 Outstanding Teacher Award, University of Washington School of Medicine, Pediatric Residency Training Program

2000 Family Choice Award from the Parent Advisory Council at Children’s Hospital & Regional Medical Center (CHRMC), Seattle, WA

2000 Voted one of Seattle’s Top Doctors per Seattle Magazine poll of peers

2001 Nominee, Family Choice Award from Parent Advisory Council at CHRMC

2002 Nominee, Family Choice Award from Parent Advisory Council at CHRMC

2004 Outstanding Teacher Award, University of Washington School of Medicine, Pediatric Residency Training Program

2005 Voted one of Seattle’s Top Doctors per Seattle Magazine poll of peers

2005 Nominee, Family Choice Award from Family Advisory Council at CHRMC

2005 Selected to the Best Doctors in America

2006 Voted one of Seattle’s Top Doctors per Seattle Magazine poll of peers

2007 Voted one of Seattle’s Top Doctors per Seattle Magazine poll of peers

2007-08 Selected to Best Doctors in America

2008 Mentoring Award from the University of Washington School of Medicine, Department of Pediatrics (recognizes outstanding mentoring of junior faculty)

2008 Voted one of Seattle’s Top Doctors per Seattle Magazine poll of peers

Grants/Research Awards

1985-1990 National Institutes of Health, Program Project (PI, W.A. Hodson):

Neonatal Pulmonary Circulation: Co-Investigator (R. Gibson)

1987 Research Training Fellowship, American Lung Association, 1987-88

1987 Research Grant, American Lung Association: The Specificity and

Bacterial Stimulus of Pulmonary Hypertension in Neonatal Sepsis

1988 Research Training Fellowship, American Lung Association, 1988-89

1988-91 RJR Nabisco Research Scholar Award: Bacterial-Host Cell

Interactions that Stimulate Proinflammatory Mediators in

Neonatal Group B Streptococcal Sepsis

1990-95 Maternal Child Health, Pediatric Pulmonary Center Training Grant

(P.I.: G. Redding, Co-I: R. Gibson)

1991-93 Research Grant, Washington Technology Center: The Role of

Pulmonary Microvascular Endothelial Cell Response in Lung Disease

1991-94 Edward Livingston Trudeau Scholar Award, American Lung

Association: Group B Streptococcus Endothelial Cell Interactions

1993-98 Co-PIs (B. Ramsey, R. Gibson)/Mentors of Leroy Matthews

Physician Scientist Award

1995-2000 Maternal Child Health, Pediatric Pulmonary Center Training Grant

(P.I.: G. Redding, Co-I: R. Gibson)

1996-97 Cystic Fibrosis Foundation Grant

Gene Therapy in the Developing Airways of Mice

1996-97 Cystic Fibrosis-Research Development Program Pilot Grant

1998- Cystic Fibrosis Clinical Care Center Grant (PI, R. Gibson)

1998-2003 Cystic Fibrosis Foundation Therapeutics Development Center

(Co-PIs R. Gibson/Moira Aitken)

1999- Director of the Clinical Core, CFF- Research Development Program

2000-2005 Maternal Child Health, Pediatric Pulmonary Center Training Grant

(P.I.: G. Redding, Co-I: R. Gibson)

1999-2002 Food and Drug Administration Orphan Product Development Grant

TOBI in Young Children with Cystic Fibrosis (Co-PI, R. Gibson)

2000-2005 National Institutes of Health: Inhaled Tobramycin in Young Cystic Fibrosis Patients (#RO1 DK57755-01, PI-B. Ramsey, Co-PI R. Gibson)

2003-2008 Cystic Fibrosis Foundation Therapeutics Development Center (Co-PIs R. Gibson/Moira Aitken, $500,000)

2003-2007 Cystic Fibrosis Foundation Therapeutics: Standard vs. Biofilm

Susceptibility Testing in CF (PI: J. Burns/Moskowitz, Co-I: R. Gibson)

2004-2009 Cystic Fibrosis Foundation Therapeutics: Early Pseudomonas

Infection Control (EPIC)-Observational Study

(PIs: M. Rosenfeld, R. Gibson)

2007-2009 Cystic Fibrosis Foundation Therapeutics: Early Pseudomonas Infection Control (EPIC)-Observational Study- DNA Collection

Amendment (PI: R. Gibson)

2009-2014 Cystic Fibrosis Foundation Therapeutics: Early Pseudomonas

Infection Control (EPIC)-Observational Study-Phase II

(PIs: M. Rosenfeld, R. Gibson)

2009-2014 Cystic Fibrosis Foundation Translational Therapeutics Development Center

(Co-PIs: R Gibson, M. Aitken).

6. Board Certification

1982 National Board of Medical Examiners

1988- Board Certified in Pediatrics (#36845)

1992-1999 Board Certified in Pediatric Pulmonology (#303)

2000-2006 Re-certified in Pediatric Pulmonology (PRCP-MS)

2007-2013 Re-certified in Pediatric Pulmonology (PRCP-MS)

7. Current License to Practice

1983-present Washington (# MD00021155)

8. Professional Organizations

National:

1986-88 American Academy of Pediatrics

1986- American Thoracic Society

1992- Pediatric Pulmonary Training Directors Association

1994-1998 American Society for Microbiology

1997- Society for Pediatric Research

Local:

1989- Washington Thoracic Society

1990- Western Society for Pediatric Research

1990- Washington Chapter, American Academy of Pediatrics

9. Teaching Responsibilities

Medical Students- Interact with 2-3 medical students each week of inpatient service with daily case-based teaching in subspecialty rounds, or in weekly Chest/CF Clinic at CHRMC

Residents- Interact closely with 6 residents on the Pulmonary Team and 1-2 additional residents on the pulmonary elective for each week of subspecialty attending (10-12 weeks the past two years). These interactions include cased-based teaching at the bedside and in outpatient clinics, and 1-2 mini-lectures per week of attending.

Pediatric Pulmonology Fellows- co-Director of fellowship program with active role in recruitment, curriculum development, evaluation of trainees, and career counseling; Goal of one first-year fellow each year.

Graduates of our Pediatric Pulmonology Program (1992-2005):

Timothy D. Murphy, M.D. Associate Professor, Univ. of Pittsburgh Margaret Rosenfeld, M.D.,M.P.H. Associate Professor, Univ. of Washington

John P. Osborn, M.D. Clinical Assoc. Professor, Univ. of Virginia

Sonia K. Budhecha, M.D. Assistant Professor, Univ. of Nevada, Reno

Toby S. Lewis, M.D., M.P.H. Assistant Professor, University of Michigan

Samuel M. Moskowitz, M.D. Assistant Professor, Univ. of Washington

Jason S. Debley, M.D., M. P. H. Assistant Professor, Univ. of Washington

Martha McKinney, M.D., M.P.H. Asst. Prof., Queens Univ., Kingston, Ontario Lucas R. Hoffman, M.D., Ph.D. Assistant Professor, Univ. of Washington

Danny Hsia, MD Oakland Children’s Hospital

DB Sanders, MD, MPH Asst. Prof, University of Wisconsin, Madison

10. Editorial Responsibilities: no editorial boards

11. Special National and Regional Committees/Activities

1992- Member, Pediatric Pulmonary Training Directors Association (PEPTDA)

1993 Member, Committee to Review the Uniformed Services Pediatric Seminar Scientific Awards Competition for the Andrew Margileth Award

1995- Coordinator/Moderator for Regional, Quarterly CF Clinical Conferences including the University of Washington Adult Program, Spokane Affiliate Program, Tacoma Affiliate Program, Anchorage Affiliate Program, and Invitees from the University of Oregon and British Columbia

1997 Site Visit to Affiliate CF Program in Spokane, WA

1998-2003 Member, Steering Committee for the Cystic Fibrosis Therapeutic Development Center Network

1998- Member, Pediatric Planning Committee for the Cystic Fibrosis Foundation (CFF) Therapeutic Development Center Network (TDN)

1998 Member, PEPTDA Workforce and Recruitment Subcommittee

1998 Chairperson, Committee to develop Standard Operating Procedure for Spirometry within the Cystic Fibrosis Foundation Therapeutic Development Network (TDN)

1998 Member, Committee to develop a Standard Operating Procedure for Nasal Potential Difference Measurements within the CFF TDN

1997. Member, Data Safety Monitoring Committee for Intrabiotics-367 Multicenter Phase I Study

1998 Speaker/Panelist at Roundtable Discussion on Guidelines for Assessing Affiliate CF Centers at the 1998 North American CF Foundation Meeting

1998 Member, Committee to Review the Uniformed Services Pediatric Seminar Scientific Awards Competition for the Andrew Margileth Award

1999 Site Visit to Affiliate CF Program in Anchorage, Alaska

1998. Visiting Professor, University of California, San Diego, including Grand Rounds at Children’s Hospital, San Diego entitled “Cystic Fibrosis: Pathophysiology and Update on Treatment”

1999 Invited Speaker for Post-Graduate Symposium on Aerosolized Antibiotics at the American Thoracic Society International Meeting

1999 Roundtable Discussion Leader on Aerosolized Antibiotics in Cystic Fibrosis at the 1999 International North American Cystic Fibrosis Foundation Meeting

2000 Site Visit to Affiliate CF Program in Spokane, WA

2000 Chairperson, Committee on Early Interventions in Cystic Fibrosis, Northwest Cystic Fibrosis Consortium, Epidemiologic Study in Cystic Fibrosis (Genentech)

2000 Invited to Cystic Fibrosis Foundation Williamsburg Conference

2000- Member, Cystic Fibrosis Foundation (CFF) Clinical Research Committee for National Review of Research Grants

2001 Invited Speaker at American Thoracic Conference, “Impact of Early Antibiotic Treatment in Young Children with Cystic Fibrosis”

2001- Member, CFF-TDN Committee to Establish Quality Control Standards for Pulmonary Function Testing

2001 Member, CFF-TDN Task Force for Re-Structuring of the Therapeutics Development Network

2002 Member, Nominating Committee for Pediatric Pulmonary Training Directors Association Officers

2002-04 Member, Steering Committee on Joint Project between the CFF and Proteome Systems (Australia)

2002 Invited Speaker at the 2002 European CF Conference in Genoa, Italy, “Tobramycin Solution for Inhalation in Young Children with CF: Eradication of Lower Airway Pseudomonas”

2002- Member, Protocol Development Committee for the CF Therapeutics Development Network

2003 Invited Speaker, “Pseudomonas Summit”, Cystic Fibrosis Foundation, Bethesda, MD

2004-2007 Member, Steering Committee for the Cystic Fibrosis Therapeutic Development Center Network

2004 Invited Speaker at the 2004 European CF Conference in Birmingham, England

“Early Intervention Strategies in CF Lung Disease”

2004 Member, National Committee to Develop Educational Slide Set on Early Intervention in Cystic Fibrosis

2004- Member, International CF Foundation Antimicrobial Task Force for Drug Development

2004- Member, Steering Committee, Early Pseudomonal Infection Control Study

2004- Chair, Publications & Presentations Committee, Early Pseudomonal Infection Control Study

2006 Faculty for CF Foundation-sponsored national training course on GCP Clinical

Research at 2006 North American CF Conference

2007-2008 Selected Site in Cystic Fibrosis (CF) Foundation Leadership & Learning Collaborative V-National Continuous Quality Improvement Project to Improve Pulmonary Outcomes in CF

2007 Co-Chairperson, Pseudomonas Workshop, Williamsburg Cystic Fibrosis Conference

2008 Workshop Leader, International Consensus Conference on Pseudomonas Serology in CF, Bethesda, MD

12. Special Local Responsibilities/Committees

1988- University of Washington Pediatric Housestaff Selection-interviewer

1988-1990 University of Washington Pediatric Intern Selection Committee

1989 WAMI Visiting Professor, Sacred Heart Medical Center, Spokane, Washington

1989 WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington

1990-2005 Associate Director, Pediatric Pulmonary Center Training Grant (MCH #539167)

1990 WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington

1991-2001 Pharmacy and Therapeutics Committee, Children's Hospital & Medical Center, Seattle, Washington

1991 Pediatric Grand Rounds at Children’s Hospital & Regional Medical Center: Update on Bronchopulmonary Dysplasia

1991 WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington

1992- Co-Director, Pediatric Pulmonary Fellowship Program, University of Washington School of Medicine, Seattle, Washington

1992- Co-Director, Pediatric Pulmonology Weekly Journal Club, Children's Hospital & Regional Medical Center, Seattle, Washington

1992 WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington

1993-5 PMD Representative to Virginia Mason, South, Children's Hospital & Medical Center, Seattle, Washington

1993 WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington

1994 Chairman, Asthma Clinical Care Pathway, Children's Hospital & Medical Center, Seattle, Washington

1994 WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington

1994-95 POD C Outpatient Clinics Workgroup, Committee Member, Children's Hospital & Medical Center, Seattle, Washington

1995 Pediatric Grand Rounds at Children’s Hospital & Regional Medical Center: Review of Asthma Clinical Pathway

1995 Speaker at Parent’s Day Educational Conference on Cystic Fibrosis

1995 WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington and Toppenish Farm Workers Clinic/Providence Hospital, Toppenish, Washington

1996 Chairman, Asthma Clinical Care Pathway Revision I, Children’s Hospital & Medical Center, Seattle, WA

1996 Member, Laboratory Space Committee for the Department of Pediatrics, University of Washington School of Medicine, Seattle, WA

1996 WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington and Toppenish Farm Workers Clinic/Providence Hospital, Toppenish, Washington

1996-1998 Associate Director of the Cystic Fibrosis Center, Children’s Hospital & Medical Center, Seattle, Washington

1996- Member, Grand Rounds Steering Committee, Children’s Hospital & Medical Center, Seattle, WA

1996 Member, Cardiovascular Surgery Quality Assurance Committee, Children’s Hospital & Medical Center, Seattle, WA

1997 Asthma Managed Care Focus Group, Children’s Hospital and Regional Medical Center, Seattle, WA

1999. Chairperson, Asthma Clinical Pathway Revision II, Children’s Hospital & Regional Medical Center, Seattle, WA

1997 Member of Internal Review Committee for Child & Adolescent Psychiatry Training Program, University of Washington/CHRMC, Seattle, WA

1998 Speaker at Parent’s Day Educational Conference on Cystic Fibrosis

1998 Team Member for Care Coordination Pilot with Asthma Patients, CHRMC, Seattle, WA

1998 Team Member for the Cystic Fibrosis Managed Care Readiness Project, CHRMC, Seattle, WA

1998 Acting Director of the Cystic Fibrosis Center, CHRMC, Seattle, WA

1998- Center Director, Pediatric Program Director for the Cystic Fibrosis Center, University of Washington, Children’s Hospital & Regional Medical Center, Seattle, WA

1998- Director/Moderator of CF Center Quarterly Regional Conferences on Clinical Care- includes Pediatric CF Center at CHRMC, Adult CF Program at UWMC, Affiliate CF Programs at Mary Bridge in Tacoma, WA, Deaconess Hospital in Spokane, WA, and invitees from Kaiser in Portland, OR and CF Centers in Victoria and Vancouver, BC, Canada.

1998 Chairperson, Cystic Fibrosis Clinical Pathway Revision Committee, CHRMC, Seattle, WA

1998- Local Spokesperson for Great Strides Fundraiser for Cystic Fibrosis

1999 Speaker at Parent’s Day Educational Conference on Cystic Fibrosis

1999 Member, Asthma Clinical Pathway Revision Committee, CHRMC, Seattle, WA

1999 CHRMC Quarterly Curbstone Consult: Chronic Cough (Editor, Dr. S. Dassel)

1999 Chairperson, CHRMC Pharmacy & Therapeutics Subcommittee for Palivizumab

(Synagis) Guidelines

1999 Speaker at 19th Annual F. Richard Dion Pediatric Update, Seattle, WA: Asthma

2000 Speaker at Parent’s Day Educational Conference on Cystic Fibrosis

2000 WWAMI Visiting Professor, Peninsula Children’s Clinic, Port Angeles, WA

2000 CHRMC Quarterly Curbstone Consult: Asthma Pathway (Editor: Dr. S. Dassel)

2001 Speaker at Parent Day Educational Conference on Cystic Fibrosis

2002 Site Visit to Affiliate CF Center, Anchorage, Alaska

2002. Invited Speaker at Puget Sound Allergy & Asthma Society Meeting: Update on the Diagnosis and Management of CF

2002 Speaker at CF Regional Quarterly Conference: Macrolides and CF

2003 Site Visit to Affiliate CF Center, Spokane, Washington

2003 Speaker, CF Quarterly Regional Conference: Early Intervention for Pseudomonas in Children with CF

2004 Member, Inpatient Medicine Project Subcommittee on Education

2004 WWAMI Visiting Professor, Yakima Pediatric Associates, Yakima, WA and Toppenish Farm Workers Clinic/Providence Hospital, Toppenish, WA

2004 Member, Cystic Fibrosis Research Faculty Search Committee, Department of Pediatrics/CHRMC (Chair: B. Ramsey)

2004 Member, Neonatal Research Faculty Search Committee (Chair: D. Woodrum), Department of Pediatrics, University of Washington School of Medicine

2004. Member, Institutional Review Board Forms Committee, CHRMC, Seattle, WA

2005. Speaker at Parent’s Day Educational Conference on Cystic Fibrosis

2005 Speaker at CF Quarterly Regional CF Conference: Hypertonic Saline in CF

2005- Director, Pediatric Pulmonary Fellowship Program, University of Washington School of Medicine, Seattle, Washington

2005-2007 Member, Scholarship Oversight Committee for Pediatric Critical Care Fellow, Iain Asplin, MD, PhD

2006- Member, CUMG Physician Education, Billing, and Compliance Committee

2006- Member, Human Subject Protection Program Advisory Committee, CHRMC

2006 WWAMI Visiting Professor, Pocatello Children & Adolescent Clinic, Pocatello, ID, and St. Luke’s Regional Medical Center, Boise, ID (3-day trip)

2006 Panel Member, R2 Pediatric Retreat on Academic Career Options

2006 Scientist/Poster Presenter at CHRMC Centennial Kick-off Research Event

2006-8 Ad hoc member, Scholarship Oversight Committee, Danny Hsia, MD

2007 Invited Speaker at 7th Annual Madigan Pediatric Update Conference: Update on the Treatment of CF Lung Disease.

2007 Speaker at Parent’s Day Educational Conference on Cystic Fibrosis

2007- Member, Steering Committee, Center for Clinical and Translational Research, Seattle Children’s Hospital Research Institute

2007 Presentation of the CHRMC Cystic Fibrosis Center Quality Improvement Program to the CHRMC Board

2007-9 Ad hoc member, Scholarship Oversight Committee, DB Sanders, MD

2008 WWAMI Visiting Professor, Peninsula Children’s Clinic, Port Angeles, WA

2008 Participant in Medical Ward Team Configuration Meeting, CHRMC

2008 Member, Review Committee for the Center for Clinical and Translational Research Mentored Scientist Program, Seattle Children’s Hospital

2008- Member, Recruitment Subcommittee for the Center for Clinical and Translational Research, Seattle Children’s Hospital

2008 Case Presenter at Sconyers/Godfrey Ethics Grand Rounds, CHRMC

2008- Member, Appointments and Promotions Committee, Depart ment of Pediatrics, University of Washington School of Medicine

2009 Speaker, CF Parent Education Day

13. Research Funding

Name of Individual: Ronald L. Gibson, MD, PhD

ACTIVE (Renewable annually)

Project Number: C117-04 Dates of Current Project: 7/1/08-6/30/09

Principal Investigator: Ronald L. Gibson, MD, PhD Percent Effort: 15%

Source: Cystic Fibrosis Foundation Direct Costs: $230,322

Title of Project: Cystic Fibrosis Center Grant

Major goals this project: Funding for ongoing support of the Cystic Fibrosis Clinical Center.

Name of Individual: Ronald L. Gibson, MD, PhD

ACTIVE

Project Number: GIBSON98Y0 Dates of Entire Project: 4/1/09-3/31/14

Principal Investigator: Ronald L. Gibson, MD, PhD Percent Effort: 10%

Source: Cystic Fibrosis Foundation Current Direct Costs: $200,000

Title of Project: Translational Therapeutic Development Center

Major goals of this project: To develop and conduct Phase I/II clinical trials in cystic fibrosis related research as part of the Cystic Fibrosis Foundation's Therapeutic Development Network.

Name of Individual: Ronald L. Gibson, MD, PhD

Role: Co-Investigator, Director of Clinical Core for Research Development Program

ACTIVE

Project Number: R565 Dates of Project: 10/1/08-9/30/09

Principal Investigator: E. Peter Greenberg, PhD Percent Effort: 5%

Source: Cystic Fibrosis Foundation Direct Costs: $42,000

Title of Project: Molecular Biology of Cystic Fibrosis: Clinical Core

Major goals of this project: To provide a national resource for development of well-designed clinical investigations in patients with CF and to foster collaboration with basic scientists to promote pilot studies by providing patient specimens or clinical data.

Name of Individual: Ronald L. Gibson, MD, PhD

Role: Co-Investigator

Project Number: BURN03A0 Dates of Project: 6/1/04-12/31/07

Principal Investigator: Jane Burns, MD Percent Effort: 3%

Source: Cystic Fibrosis Foundation Direct Costs: $228,355

Title of Project: Standard versus Biofilm Susceptibility Testing in Cystic Fibrosis

Major goals of this project: To compare the microbiological efficacy, clinical efficacy, and safety of using standard versus biofilm susceptibility testing of P.aeruginosa sputum isolates to guide antibiotic selection of airway infection in clinically stable patients with CF.

Name of Individual: Ronald L. Gibson, MD, PhD

Role: Co-Principal Investigator

Dates of Project: 4/1/09-3/30/14 Percent Effort: 15%

Source: Cystic Fibrosis Foundation Direct Costs: $1,328,747

Title of Project: EPIC Observational Study

Major goals of this project: A large, multicenter, prospective, descriptive study of the risk factors for and outcomes associated with initial acquisition of Pseudomonas aeruginosa as well as outcomes associated with therapy among CF patients 1 to 12 years of age.

GIBSON07K0 (Gibson – PI) 9/1/07 – 8/31/09

Cystic Fibrosis Foundation Percent Effort: 5%; Direct Costs: $650,000

DNA Collections for Gene Modifier Studies

The goal of this project is to collect DNA samples from children with cystic fibrosis (CF) who are currently participating in the Early Pseudomonas Infection Control (EPIC)

Role: PI

Current ADDITiONAL Clinical Studies: Percent Effort: 10%

Sponsor: Cystic Fibrosis Foundation

Title of Study: Quality of Life in Adults and Adolescents with Severe Cystic Fibrosis

Sponsor: NIH/John Hopkins University

Title of Study: Genetic Modifiers of Cystic Fibrosis (CF Twin/Sibling Study)

Sponsor: Corus Pharma, Inc.

Title of Study: CP-AI-006 - A Phase 3, Open-label, Follow-on Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR-CF3)

Sponsor: Inspire Pharmaceuticals

Title of Study: A Phase 3, Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Denusoful in Patients with Cystic Fibrosis

14. Bibliography

a) Peer-Reviewed Publications

1. Gibson, R, Leavitt, R, Kornfeld, S, and Schlesinger, S: Synthesis and infectivity of vesicular stomatitis virus containing nonglycosylated G protein. Cell 13:671-679, 1978.

2. Gibson, R, Schlesinger, S, and Kornfeld, S: The nonglycosylated glycoprotein of vesicular stomatitis virus is temperature sensitive and undergoes intracellular aggregation at elevated temperatures. J. Biol. Chem. 254:3600-3607, 1979.

3. Li, E, Gibson, R, and Kornfeld, S: Structure of an unusual complex-type oligosaccharide isolated from Chinese hamster cells. Arch. Biochem. Biophys. 199:393-399, 1980.

4. Gibson, R, Kornfeld, S, and Schlesinger, S: A role for oligosaccharides in glycoprotein biosynthesis. TIBS 5:290-293, 1980.

5. Gibson, R, Kornfeld, S, and Schlesinger, S: The effect of oligosaccharide chains of different sizes on the maturation and physical properties of the G protein of vesicular stomatitis virus. J. Biol. Chem. 256:456-462, 1981.

6. Gibson, RL, Truog, WE, and Redding, GJ: Hypoxic pulmonary vasoconstriction during and following infusion of group B streptococcus in neonatal piglets: vascular pressure-flow analysis. Am. Rev. Respir. Dis.137:774-778, 1988.

7. Gibson, RL, Truog, WE, and Redding, GJ: Thromboxane-associated pulmonary hypertension during three types of gram-positive bacteremia in piglets. Pediatr. Res., 23:553-556, 1988.

8. Truog, WE, Gibson, RL, Juul, SE, Henderson, WR, and Redding, GJ: Neonatal group B streptococcal sepsis: Effects of late treatment with dazmegrel. Pediatr. Res., 23:352-356, 1988.

9. Gibson, RL, Jackson, JC, Twiggs, GA, Redding, GJ, and Truog, WE: Bronchopulmonary dysplasia: survival after prolonged mechanical ventilation. Am. J. Dis. Child., 142:721-725, 1988.

10. Redding, GJ, Gibson, RL, Davis, CB, and Truog, WE: Effects of respiratory alkalosis on thromboxane-induced pulmonary hypertension in piglets. Pediatr. Res., 24(5):558-562, 1988.

11. Gibson, RL, Redding, GJ, Truog, WE, Henderson, WR, and Rubens, CE: Isogenic group B streptococci devoid of capsular polysaccharide or β-hemolysin: pulmonary hemodynamic and gas exchange effects during bacteremia in piglets. Pediatr. Res., 26(3):241-245, 1989.

12. Redding, GJ, Gibson, RL, Standaert TA, Truog, WE: Regional pulmonary blood flow in piglets during group B streptococcal bacteremia. Am. Rev. Respir. Dis. 141:1209-1213, 1990.

13. Truog, WE, Gibson, RL, Henderson, WR, Redding, GJ: Tumor necrosis factor-induced neonatal pulmonary hypertension: effects of dazmegrel pre-treatment. Pediatr. Res. 27(5):466-471, 1990.

14. Redding, GJ, Walund, L, Walund, D, Jones, JW, Stamey, DC, and Gibson, RL: Lung function in children following empyema: influence of pleural drainage. Amer. J. Dis. Child. 144:1337-1342, 1990.

15. Gibson, RL, Redding, GJ, Henderson, WR, Truog, WE: Group B streptococcus induces tumor necrosis factor (TNF) in neonatal piglets: effect of the TNF inhibitor, pentoxifylline on hemodynamics and gas exchange. Am. Rev. Respir. Dis. 143:598-604, 1991.

16. Ramsey, B, Wentz, K, Smith, A, Richardson, M, Williams-Warren, J, Hedges, D, Gibson, R, Redding, GJ: Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis. Am. Rev. Respir. Dis., 144:331-337, 1991.

17. Standaert, TA, Willham, BE, Mayock, DE, Watchko, JF, Gibson, RL, Woodrum, DE: Respiratory mechanics of the piglet during the first month of life. Pediatr. Pulm. 11:294-301, 1991.

18. Truog, WE, Gibson, RL, Henderson, WR, Redding, GJ, Standaert, TA: Effect of pentoxifylline on cytokine and eicosanoid induced acute pulmonary hypertension in piglets. Pediatric Res. 31(2):163-169, 1992.

19. Gibson, RL, Truog, WE, Henderson, WR, Redding, GJ: Group B streptococcal sepsis in piglets: effect of combined pentoxifylline and indomethacin pretreatment. Pediatr. Res. 31(3):222-227, 1992.

20. Murphy, TD, Mayock, DE, Standaert, TA, Gibson, RL, Woodrum, DE: Group B streptococcus has no effect on piglet diaphragmatic force generation. Am. Rev. Resp. Dis. 145:471-475, 1992.

21. Gibson, RL, Lee, MK, Soderland, C, Chi, EY, Rubens, CE: Group B streptococci invade endothelial cells: type III capsular polysaccharide attenuates invasion. Infection & Immunity, 61(2):478-485, 1993.

22. Murphy, TD, Gibson, RL, Standaert, TA, Mayock, DE, Woodrum, DE: Effect of group B streptococcal sepsis on diaphragmatic function in young piglets. Pediatr. Res. 33(1):10-14, 1993.

23. Berger, JI, Gibson, RL, Redding, GJ, Standaert, TA, Clarke, WR, Truog, WE: Effect of inhaled nitric oxide during group B streptococcal sepsis in piglets. Amer. Rev. Respir. Dis. 147:1080-1086, 1993.

24. Ramsey, BW, Astley, SJ, Aitken, MR, Burke, W, Colin, AA, Dorkin, HL, Eisenberg, JD, Gibson, RL, et al.: Efficacy and safety of short term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis (CF). Amer. Rev. Respir. Dis. 148:145-151, 1993.

25. Ramsey, BW, Dorkin, HL, Eisenberg, JD, Gibson, RL, Harwood, IR, Kravitz, RM, Schidlow, DV, Wilmott, RW, Astley, SJ, McBurnie, MA, Wentz, K, Smith, AL: The efficacy of high dose tobramycin aerosol administration in patients with cystic fibrosis. N. Engl. J. Med. 328(24):1740-1746, 1993.

26. Berger, JI, Gibson, RL, Clarke, WR, Standaert, TA, Redding, GJ, Henderson, WR, Truog, WE: Effect of amrinone during group B streptococcus induced pulmonary hypertension in piglets. Peds Pulmonol 16(5):303-310, 1993.

27. Gibson, RL, Davis, CB, Standaert, TA, Truog, WE, Redding, GJ: Lung vascular responses and A/ matching after chronic hypoxia in neonatal piglets. J. Develop. Physiol. 19(4):157-163, 1993.

28. Fuchs, HJ, Borowitz, DS, Christiansen, DH, et al. and the Pulmozyme Study Group (RL Gibson, member): Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 331:637-742, 1994.

29. Gibson, RL, Berger, JI, Redding, GJ, Standaert, TA, Mayock, DE, Truog, WE: Effect of nitric oxide synthase inhibition during group B streptococcal sepsis in neonatal piglets. Pediatr Res 36: 776-783, 1994.

30. Murphy, TD, Gibson, RL, Standaert, TA, Woodrum, DE: Diaphragmatic failure during group B streptococcal sepsis in piglets: the role of thromboxane A2. J Appl Physiol 78 (2): 491-498, 1995.

31. Gibson, RL, Soderland, C, Henderson, WR, Chi, EY, Rubens, CE: Group B streptococci injure lung endothelium in vitro: increased invasion and eicosanoid production with microvascular compared to pulmonary artery cells. Infect Immun 63:271-279, 1995.

32. Juul, SE, Kinsella MG, Truog WE, Gibson RL, Redding GJ. Lung hyaluronan decreases during group B streptococcal pneumonia in neonatal piglets. Amer J Respir Crit Care Med 153: 1567-70, 1996.

33. Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, Launspach J, Moscicki RA, Richards SM, Standaert TA, Williams-Warren J, Wadsworth SC, Smith AE, Welsh MJ. Repeat administration of an adenovirus vector encoding CFTR to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 97 (6): 1504-11, 1996.

34. Nizet V, Gibson RL, Chi EY, Framson PE, Hulse M, Rubens CE. Group B streptococcal β-hemolysin expression is associated with injury to lung epithelial cells. Infect Immun 64(9): 3818-3826, 1996.

35. Nizet V, Gibson RL, Rubens CE. The role of group B streptococci beta-hemolysin expression in newborn lung injury. Adv Exp Med Biol 418:627-630, 1997.

36. Gibson RL, Nizet VF, Rubens CE. Group B streptococcal β-hemolysin promotes injury of lung microvascular endothelial cells. Pediatric Research 45:626-634, 1999.

37. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, Ramsey BW. Longitudinal assessment of Pseudomonas aeruginosa in infants with cystic fibrosis. Journal of Infectious Diseases 183: 444-52, 2001.

38. Noone PG, Hamblett N, Accurso F, Aitken M, Boyle M, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan M, Milgram L, Mundahl J, Rodman D, Williams-Warren J, Wilmott R, Zeitlin P, Ramsey R. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center trial. Pediatric Pulmonology 32: 122-8, 2001.

39. Rosenfeld M, Gibson RL, McNamara S, Emerson J, McCoy K, Schell R, Borowitz D, Konstan M, Retsch-Bogart G, Wilmott R, Burns JL, Ramsey B. Serum and lower respiratory tract drug concentrations produced by tobramycin for inhalation in young children with cystic fibrosis. Journal of Pediatrics 139 (4): 572-7, 2001.

40. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A, Martin TR, Ramsey, BW. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatric Pulmonology 32: 356-366, 2001.

41. Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. A Phase I study of aerosolized administration of tgAAVCF to CF subjects with mild lung disease. Human Gene Therapy 12:1907-1916, 2001.

42. Brogan TV, Finn LS, Pyskaty Jr DJ, Redding GJ, Ricker D, Ingliss A, Gibson RL.

Plastic bronchitis in children: a case series and review of the medical literature.

Pediatric Pulmonology 34: 482-487, 2002.

43. Conway K, Gibson RL, Perkins J, Cunningham ML. Pulmonary agenesis: expansion of the VCFS phenotype. American Journal of Medical Genetics 113: 89-92, 2002.

44. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity among young children with cystic fibrosis. Pediatric Pulmonology 34:91-100, 2002.

45. Aitken ML, Tonelli MR, Pier MV, Burns JL, Emerson JC, Goss CH, McNamara SC, Gibson RL. Analysis of sequential aliquots of hypertonic saline induced sputum from stable patients with cystic fibrosis. Chest 123:792-799, 2003.

46. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B, and the CFF Therapeutics Development Network Study Group. A significant microbiologic effect of inhaled tobramycin in young children with cystic fibrosis. Am JResp Crit Care Med 167:841-849, 2003.

47. Cunningham ML, Perry RJ, Eby PR, Gibson RL, Opheim KE, Manning SC. Primary pulmonary dysgenesis in velocardiofacial syndrome: a second patient. American Journal of Medical Genetics 121A:177-9, 2003.

48. Ordoñez CL, Henig NR, Gibson RL, Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines C, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML. Validation of sputum induction as an outcome measure for lower airway sampling in subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 168:1471-5, 2003.

49. Gibson RL, Burns JL, Ramsey BW. State of the Art: Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 168: 918-951, 2003.

50. Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas aeruginosa acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Current Opinion in Pulmonary Medicine 9(6):492-7, 2003.

51. Moss, RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL. et al. A randomized, double-blind, placebo-controlled, dose escalating study of aerosolized interferon (-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 39(3):209-218, 2005.

52. Deterding R, Retsch-Bogart G, Milgram L, Gibson RL, et al. Safety and tolerability of Denufosol tetrasodium inhalational solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multi-center study in mild to moderate cystic fibrosis. Pediatr Pulmonol 39(4):339-348, 2005.

53. Moskowitz SM, Gibson RL, Effman E. Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiologic assessment. Pediatr Radiol 35(8):739-757, 2005.

54. Debley JS, Carter ER, Gibson RL, Rosenfeld M, Redding GJ. The prevalence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocation challenge study. J. Pediatr 147:233-8, 2005

55. Kulich M, Rosenfeld M, Campbell J, Kronmall R, Gibson RL, Goss CH, Ramsey BR. Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Resp Crit Care Med 172:885-91, 2005.

56. Hoffman LR, Yen E, Van Niel C, Effman, E, Gibson RL. Lipoid pneumonia due to Mexican folk remedies: cultural barriers to diagnosis. Arch Pediatr Adolesc Med 159(11):1043-8, 2005.

57. Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 56(5):879-886, 2005.

58. Halbert CL, Miller AD, McNamara S, Emerson J, Gibson RL, Ramsey B, Aitken ML. Prevalence of Neutralizing Antibodies to Adeno-associated Virus Types 2, 5 and 6 in Cystic Fibrosis and Normal Populations: Implication for Gene Therapy using AAV Vectors. Human Gene Therapy 17(4):440-7, 2006.

59. Gibson RL, Retsch-Bogart G, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 41:656-665, 2006.

60. Hoffman LR, Deziel E, D’Argenio DA, Lepine F, Emerson J, McNamara S, Gibson RL, Ramsey BW, Miller SI. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 103(52): 19890-5, 2006.

61. Hentschel-Franks K, Bebok Z, Rowe SM, Gibson R, Aitken M, Zeitlin P, Berclaz Y, Knowles M, Foy G, Moss R, Oster R, Ramsey B, Sorscher EJ, Bedwell DM, Clancy JP. No detectable improvements in CFTR by nasal aminoglycosides in CF patients with stop mutations. Am J Resp Cell Mol Biol 37(1):57-66, 2007.

62. Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart GZ, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, and Ramsey BW for the Inhaled Tobramycin in Young Children Study Group and the Cystic Fibrosis Foundation Therapeutics Development Network. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 42(7):610-23, 2007.

63. Treggiari M, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B and the EPIC Clinical Trial Group. Approach to eradication of initial Pseudomonas aeruginosa in children with cystic fibrosis. Pediatr Pulmonol, 42(9): 751-6, 2007.

64. Dovey M, Aitken ML, Emerson J, McNamara S, Waltz DA, Gibson RL. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbations: a pilot study. Chest 132:1212-8, 2007.

65. Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient and economic outcomes. Genetics in Medicine 9(10):695-704, 2007.

66. Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa Infection. Pediatr Pulmonol 43(1): 47-58, 2008.

67. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine is effective in intensely-treated patients with cystic fibrosis. Am J Resp Crit Care Med 178(9): 921-8, 2008.

68. Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genetics in Medicine 10(12): 851-68, 2008.

69. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW. Impact of Pseudomonas and polymicrobial infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 154(2): 183-8, 2009.

70. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest, in press, 2009.

71. Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson RL, Mayer-Hamblet N, Williams J, Emerson J, Kronmal R, Ramsey B for the EPIC Study Group. Early Anti-Pseudomonal Intervention in Young Patients with Cystic Fibrosis (EPIC): Rationale and Design of the Clinical Trial and Observational Study. Contemporary Clinical Trials, in press, 2009.

b) Book Chapters

1. Schlesinger, S, and Gibson, R: A role for oligosaccharide in the synthesis of the G protein of vesicular stomatitis virus. In: The replication of negative strand viruses. DHL Bishop and RW Compans (eds.), Elsevier North Holland, Inc., pp. 665-672, 1981.

2. Nizet, V, Gibson RL, Rubens CE. The role of GBS β-hemolysin expression in newborn lung injury. In: Streptococci and the Host. T Horaud, M Sicard, A Bouvet, R Lelerq, H DeMontclos (eds) Plenum Publishing Co., New York, pp 627-629, 1997.

3. Tait J, Gibson RL, Marshall SG, Sternen DL, Cheng E, Cutting G. Cystic Fibrosis. In: Gene Clinics: Medical Genetics Information Resource [database online]. Copyright , University of Washington, Seattle. Available at 2001.

4. Moskowitz S, Gibson RL, Sternen DL, Cheng E, Cutting G. CFTR-Related Disorders. In: Gene Clinics: Medical Genetics Information Resource [database online]. Copyright , University of Washington, Seattle. Available at , August 2004.

5. Gibson RL. Cystic Fibrosis. In: Pediatrics. L Osborn, T DeWitt, L First, J Zenel (eds). Elsevier Mosby, Philadelphia (pub), pp1198-1207, 2005.

d) Other Publications (including being member of a large Study Group)/Book Reviews

1. Gibson, RL. Review of Kendig’s Disorders of the Respiratory Tract in Children, Sixth Edition. Chernick, V, Boat, T (editors). W.B. Saunders, Philadelphia, PA.

Doody Review Service (). 1997.

2. Gibson, RL. Review of Pediatric Respiratory Medicine. Taussig, L and Landau, L (editors). Mosby, St. Louis, MO. Doody Review Service (). 1999.

3. Drumm ML, Konstan MW, Schluchter MD, et al, and Knowles MR for the Gene Modifier Study Group (includes Gibson RL). Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005; 353:1443-53.

4. Vanscoy LL, Blackman SM, Collaco JM et al. (Gibson RL was a member of the CF Twin/Sibling Study Group). Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 175:1036, 2007.

5. Goss CH, McKone EF, Mathews D, Kerr D, Wanger JS, Millard SP; Cystic Fibrosis Therapeutics Development Network (Gibson RL was one of 14 collaborators). Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis. J Cystic Fibrosis 7(2):147-53, 2008.

e) Submitted Manuscripts

1. McCoy K, Retsch-Bogart G, Gibson RL, Oermann C, Braff M, Montgomery AB. Relevance of established susceptibility breakpoints in predicting clinical efficacy of inhaled antibiotics therapies in cystic fibrosis. Re-submit to Antimicrobial Agents and Chemotherapy, February 2009.

2. Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH. Return of FEV1 after Pulmonary Exacerbation in Children with Cystic Fibrosis. Submitted, March 2009.

3. Rosenfeld M, Emerson J, McNamara S, Joubran K, Morgan W, and Gibson RL for the EPIC Study Group. Early Pseudomonas Infection Control Observational Study: Baseline Report. Submitted, March 2009.

f) Abstracts

1. Zitomer, RS, Gibson, RL, and Hall, BD: In vitro translation of cytochrome mRNA. Presented. Cold Spring Harbor Symposium: The Molecular Biology of Yeast, page 28, 1975.

2. Gibson, RL, Schlesinger, S, and Kornfeld, S: The nonglycosylated glycoprotein of VSV is temperature-sensitive and undergoes aggregation at elevated temperatures. Presented 8th Annual ICN-UCLA Symposia on Molecular and Cellular Biology. Journal of Supermolecular Structure, supplement 3, page 96, 1979.

3. Redding, GJ, Gibson, R, Twiggs, G, Standaert, TA, and Truog, WE: Reduced pulmonary blood flow improves gas exchange in newborn piglets. Presented. American Thoracic Society, 1986. Am. Rev. Resp. Dis. 133(4), Part 2:A151, 1986.

4. Gibson, RL and Redding, GJ: Hypoxic pulmonary vasoconstriction persists following infusion of Group B streptococcus in neonatal piglets. J. Critical Care 1(1):32, 1987.

5. Gibson, RL, Truog, WE, and Redding, GJ: Nonspecific thromboxane-mediated pulmonary hypertension in neonatal gram-positive sepsis. Am. Rev. Resp. Dis., 135(4), Part 2:A124, 1987.

6. Redding, GJ, Gibson, RL, Standaert, TA, and Truog, WE: Lobar inflammation produced by zymosan-activated serum increases shunt fraction in piglets with lobar atelectasis. Am. Rev. Resp. Dis., 135(4), Part 2:A124, 1987.

7. Redding, GJ, Gibson, RL, and Truog, WE: Group B streptococcus (GBS) induced pulmonary hypertension does not alter shunt produced by atelectasis in piglets. Am. Rev. Resp. Dis., 135(4), Part 2:123, 1987.

8. Truog, WE, Gibson, RL, Juul, SE, Henderson, W, and Redding, GJ: Neonatal group B streptococcal (GBS) sepsis: Therapeutic implications of thromboxane synthetase (TxA2) inhibition. Pediatr. Res. 21(4), Part 2:468A, 1987.

9. Redding, GJ, Gibson, RL, Standaert, TA, and Truog, WE: Effects of hyperventilation upon pulmonary vasoconstriction induced by a thromboxane mimetic in piglets. Presented. American Thoracic Society, 1988. Am. Rev. Respir. Dis. 137(4) Part 2:105, 1988.

10. Standaert, TA, Willham, BE, Mayock, DE, Gibson, RL, and Woodrum, DE: Lung volume and pulmonary compliance of the piglet during the first month of life. Presented. American Thoracic Society, 1988. Am. Rev. Respir. Dis. 137(4) Part 2:382, 1988.

11. Redding, GJ, Davis, CB, Juul, SE, Gibson, RL, Truog, WE: Effects of angiotensin on pulmonary hemodynamics and gas exchange in piglets. Presented. American Thoracic Society. 1989. Am. Rev. Respir. Dis. 139(4), Part 2:A440, 1989.

12. Davis, CB, Gibson, RL, Truog, WE, Redding, GJ: Chronic hypoxia induced changes in the pulmonary hemodynamics of neonatal swine: pressure flow analysis. Presented. American Thoracic Society, 1989. Am. Rev. Respir. Dis. 139(4), Part 2:A437, 1989.

13. Gibson, RL, Redding, GJ, Truog, WE, Rubens, CE: A type III group B streptococcus (GBS) mutant devoid of capsular polysaccharide causes pulmonary hypertension and hypoxemia in piglets. Presented. American Thoracic Society, 1989. Am. Rev. Respir. Dis. 139(4), Part 2:A439, 1989.

14. Gibson, RL, Redding, GJ, Truog, WE: Tumor necrosis factor (TNF): potential mediator of neonatal group B streptococcal (GBS) sepsis. Presented. American Thoracic Society, 1989. Am. Rev. Respir. Dis. 139(4), Part 2:A439, 1989.

15. Truog, WE, Gibson, RL, Henderson, WR, Redding, GJ: Tumor necrosis factor-induced neonatal pulmonary hypertension: effects of dazmegrel pretreatment. Presented. Society for Pediatric Research, 1989. Pediatr. Res. 25(4), Part 2:329A, 1989.

16. Redding, GJ, Gibson, RL, Davis, CB, Standaert, TA, Truog, WE: Reduced cardiac output does not alter distribution of pulmonary blood flow to atelectatic lung regions in piglets. Presented. 1990 World Conference on Lung Health -- American Thoracic Society. Am. Rev. Respir. Dis. 141(4), Part 2:A740, 1990.

17. Murphy, TD, Standaert, TA, Gibson, RL, Mayock, DE, Woodrum, DE: Group B streptococcal (GBS) sepsis impairs diaphragmatic function in the piglet. Presented. 1990 World Conference on Lung Health -- American Thoracic Society. Am. Rev. Respir. Dis. 141(4), Part 2:A549, 1990.

18. Gibson, RL, Redding, GJ, Henderson, WR, Truog, WE: Combined pentoxifylline and indomethacin pretreatment attenuates early and late features of group B streptococcal sepsis in piglets. Presented. 1990 World Conference on Lung Health -- American Thoracic Society. Am. Rev. Respir. Dis. 141(4), Part 2:A688, 1990.

19. Davis, CB, Gibson, RL, Redding, GJ, Standaert, TA, Truog, WE: Effects of acute and chronic alveolar hypoxia on gas exchange in neonatal swine. Presented. 1990 World Conference on Lung Health -- American Thoracic Society. Am. Rev. Respir. Dis. 141(4), Part 2:A852, 1990.

20. Gibson, RL, Redding, GJ, Truog, WE, Rubens, CE: Neonatal group B streptococcal (GBS) sepsis: the role of GBS capsular polysaccharide in tumor necrosis factor (TNF) production in piglets. Presented. Federation of American Societies for Experimental Biology, 1990. FASEB Journal 4:A355, 1990.

21. Truog, WE, Redding, GJ, Standaert, TA, Gibson, RL: Effect of pentoxifylline on tumor necrosis factor-induced pulmonary hypertension in piglets. Presented. Federation of American Societies for Experimental Biology, 1990. FASEB Journal 4:A573, 1990.

22. Redding, GJ, Gibson, RL, Standaert, TA, Truog, WE: Atelectasis does not inhibit pulmonary inflammation due to experimental streptococcal pneumonia. Am. Rev. Respir. Dis. 143(4), Part 2:A787, 1991.

23. Gibson, RL, Truog, WE, Standaert, TA, Redding, GJ, Rubens, CE: Endothelial cell invasion by group B streptococci. Presented. Society for Pediatric Research, 1991. Pediatr. Res. 29(4), Part 2:A281, 1991.

24. Murphy, TD, Standaert, TA, Gibson, RL, Mayock, DE, Woodrum, DE: Group B streptococcal shock impairs diaphragmatic contractility in the piglet. Am. Rev. Respir. Dis. 143(4), Part 2:A560, 1991.

25. Berger, JI, Clarke, WR, Gibson, RL, Standaert, TA, Redding, GJ, Truog, WE: Effects of amrinone on pulmonary vascular resistance and V/Q matching during group B streptococcal sepsis in piglets. Presented. Society for Pediatric Research, 1991. Pediatr. Res. 29(4), Part 2:A308, 1991.

26. Murphy, TD, Gibson, RL, Standaert, TA, Mayock, DE, Woodrum, DE: The thromboxane A2 mimetric, U46619, decreases piglet diaphragmatic contractility. Presented. American Thoracic Society, 1992. Am. Rev. Respir. Dis. 145(4) Part 2:A671, 1992.

27. Berger, JI, Gibson, RL, Standaert, TA, Redding, GJ, Clarke, WR, Truog, WE: Effect of inhaled nitric oxide on pulmonary vascular resistance (PVR) during group B streptococcal (GBS) sepsis in piglets. Presented. The Society for Pediatric Research, 1992. Pediatr. Res. 31(4), Part 2:301A, 1992.

28. Berger, JI, Gibson, RL, Redding, GJ, Standaert, TA, Truog, WE: Effect of Nω-Nitro-L-Arginine Methyl Ester (L-NAME) on pulmonary hemodynamics during group B streptococcal (GBS) sepsis in piglets. Presented. Society for Pediatric Research, 1993. Pediatr. Res. 33(4):317A, 1993.

29. Gibson, RL, Soderland, C, Henderson, WR, Rubens, CE: Group B streptococci (GBS) invade lung endothelium in vitro: increased invasion and eicosanoid release from microvascular compared to pulmonary artery cells. Presented. American Thoracic Society, 1993. Amer. Rev. Respir. Dis. 147(4):A132, 1993.

30. Gibson, RL, Soderland, C, Rubens, CE: Specific transposon mutants of group B streptococcus (GBS) cause reduced lung microvascular endothelial cell injury in vitro. Am. J. Resp. Crit Care Med. 149:A294, 1994.

31. Nizet, V, Gibson, RL, Chi EY, Rubens CE. Expression of group B streptococcal hemolysin is associated with alveolar epithelial cell injury. Presented at the American Society of Microbiology, 1995.

32. Gibson, RL, Nizet, V, Rubens CE. Group B streptococcal β-hemolysin contributes to GBS-induced lung microvascular endothelial cell injury in vitro. Presented at the Society for Pediatric Research, 1995. Pediatr Res 37 (4): 291A, 1995.

33. Nizet, V, Gibson, RL , Framson, PE, Chi, EY, Rubens CE. Group B streptococcal hemolysin expression is correlated with epithelial cell injury. Presented at the Society for Pediatric Research 1995. Pediatr Res 37 (4): 296A, 1995.

34. Nizet, V, Gibson, RL, Rubens, CE. Group B β-hemolysin expression and injury of newborn lung. Presented at the Society for Pediatric Research May 1996 (abstract 15410).

35. Nizet, V, Gibson, RL, Rubens, CE. The role of GBS β-hemolysin expression in newborn lung injury. Presented at the XIIIth International Lancefield Society Meeting, Paris, France, Abstact # P109, 1996.

36. Ramsey, B., McNamara,S, Gibson, R, Emerson, J, Rosenfeld, M, Hiatt, P, McConnell, R, McKoy, K, Lawrence C, Olson, P. P. aeruginosa colonization in young children with cystic fibrosis. Pediatr Pulmonol, Supplement 17: page 320 (abstract #415), 1998.

37. Rosenfeld, M, Borowitz, D, Emerson, J, Gibson, R. Ingham, L, McCoy, K, McNamara, S. Montgomery, B, Ramsey, B, Vicini ,P, Wilmott, B. Safety and serum pharmacokinetics of inhaled tobramycin in very young CF patients. Presented at the 1999 North American Cystic Fibrosis Meeting. Pediatr Pulmonol, supplement 19, page 262 (abstract #346), 1999.

38. Lewis, TC, Rosenfeld M, Gibson, RL, Ramsey, BW. Urban/Rural differences in specialty health care utilization and health outcomes in cystic fibrosis. Presented at the 1999 North American Cystic Fibrosis Meeting. Pediatr Pulmonol, Supplement 19, page 337 (abstract #600), 1999.

39. Moss, R, Kylstra, J, Gibson, RL. Who benefits more? An analysis of FEV1 and weight in adolescent CF patients using inhaled tobramycin. Presented at the 1999 North American Cystic Fibrosis Meeting. Pediatr Pulmonol, Supplement 19, page 243 (abstract #279), 1999.

40. Noone, PG, Accurso FJ, Aitken M, Dovey M, Gibson, RL, Konstan M, Rodman, DM, Wilmott R, Zeitlin P, Gorden J, Shaffer C. Safety of aerosolized INS365 in patients with mild to moderate CF: results of a multi-center therapeutic development network study.

Pediatr Pulmonol, Supplement 19, page 244 (abstract # 283), 1999.

41. Aitken, ML, Moss, RB, Waltz, DA, Dovey, ME, Tonelli, MR, Gibson, RL, Ramsey, BW, Carter, BJ, Reynolds, TC. A Phase I study of aerosolized administration of tgAAVCF to CF patients with mild lung disease. Pediatr Pulmonol, Supplement 20, page 236, abstract # 226, 2000.

42. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castille R, Hiatt P, McCoy K, Wilson CB, Smith AL, Ramsey BW. Early course of pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol, supplement 20, S5.4 pages 112-114, 2000.

43. Aitken ML, Tonelli MR, Pier MV, Burns JL, Emerson JC, Goss CH, McNamara SC, Gibson RL. Analysis of sequential aliquots of hypertonic saline induced sputum from stable patients with cystic fibrosis. Pediatr Pulmonol., Supplement 22, abstract # 381, page 302, 2001.

44. Gibson, RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Moss R, Konstan M, Retsch-Bogart G, Waltz D, Wilmott R, Wagener J, Zeitlin P, Ramsey B. A randomized controlled trial of inhaled tobramycin in young children with cystic fibrosis: eradication of Pseudomonas from the lower airway.

Presented at the North American CF Conference in October 2002. Pediatr Pulmonol., Supplement 24, abstract #356, page 300, 2002.

45. Ordonez C, Gibson RL, Emerson J, McNamara S, Accurso F, Burns JL, Zeitlin P, Daines C, Retsch-Bogart G, Chmiel J, Henig N, Aitken M. Validation of sputum induction as an outcome measure for lower airway sampling in patients with cystic fibrosis. Presented at the North American CF Conference in October 2002. Pediatr Pulmonol., Supplement 24, abstract # 354, page 299, 2002.

46. Cassidy J, Gibson RL, Moskowitz S. Clinical pathway for cystic fibrosis pulmonary exacerbation. Pediatr Pulmonol., Supplement 24, abstract # 510, page 355, 2002.

47. Moss R, Wagener J, Daines C, Hale K, Ahrens R, Gibson R, Retsch-Bogart G, Nasr S, Noth I, Waltz D, Zeitlin P, Ramsey B, Hamblett N, Starko K. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild-moderate cystic fibrosis lung disease. Am J Resp Crit Care Med 2003; 167:A923.

48. Rosenfeld M, Emerson J, McNamara S, Castile R, McCoy K, Hiatt P, Burns JL, Gibson RL, Ramsey BW. Longitudinal follow-up of Pseudomonas aeruginosa infection in young children with cystic fibrosis. Am J Resp Crit Care Med 2003; 167:A164

49. Hoffman LR, Emerson JE, Gibson RL, Redding GJ. Frequency of return to best PFT baseline after CF cleanout: a pilot quality improvement project. Am J Respir Crit Care Med 2003;167:A923.

50. Moskowitz SM, Foster J, Emerson J, McNamara S, Gibson RL, Burns JL. Discordance of conventional and biofilm antibiotic susceptibilities of Pseudomonas aeruginosa isolated from cystic fibrosis airways. Am J Resp Crit Care Med 2003; 167:A322.

51. Clancy JP, Eubanks VL, Bebok Z, Franks K, Zeitlin P, Brass L, Aitken M, Gibson R, Gordon M, Davies Z, Sorscer EJ, Bedwell DM. A randomized double-blind trial of topical gentamicin and tobramycin to improve CFTR function in CF patients with and without premature stop mutations. Pediatr Pulmonol, Supplement 25, abstract # 193, 2003.

52. Sagel S, Emerson J, Rosenfeld M, McNamara S, Caron H, Ramsey B, Wagener J, Gibson R. Association of upper versus lower airway Pseudomonas aeruginosa infection with endobronchial inflammation and clinical status in young children with CF. Pediatr Pulmonol, supplement 25, abstract # 375, 2003.

53. Rosenfeld M, Caron H, Emerson J, Hamblett H, Burns JL, Gibson R, McNamara S, Hiatt P, McCoy K, Castile R, Ramsey B. What effect do anti-pseudomonal antibiotics have on serial upper airway cultures in infants with CF? Pediatr Pulmonol, supplement 25, abstract # 374, 2003.

54. Waltz DA, Gibson R, McNamara S, Campbell J, Hamblett N, Ramsey B. Safety and yield of clinical trial bronchoalveolar lavage procedures in young cystic fibrosis patients. Pediatr Pulmonol, supplement 25, abstract # 393, 2003.

55. Gibson RL, Emerson J, McNamara S et al. Duration of the anti-pseudomonal treatment effect of inhaled tobramycin in young children with cystic fibrosis. Pediatr Pulmonol, supplement 25, abstract # 323, 2003.

56. Moskowitz SM, Foster J, Emerson J, Gibson RL, McNamara S, Burns JL. Development of a numerical algorithm to select antibiotic regimens based on biofilm susceptibilities of CF P. aeruginosa isolates. Pediatr Pulmonol, supplement 25, abstract # 335, 2003.

57. Gibson, RL. Early CF lung disease: detection, pathogenesis, and treatment. Presented at Symposium at 2004 NACFC, October 15, 2004. Pediatr Pulmonol, supplement 27, S3.1, page 105, 2004.

58. Gibson, RL, Ahrens, R, Clancy JP et al. Safety and tolerability of aztreonam for inhalation (AI) in cystic fibrosis patients. Presented at 2004 NACFC Conference. Pediatr Pulmonol, supplement 27, abstract 189, 2004.

59. Dovey, M, Aitken ML, Emerson J, McNamara S, Dorman D, Gibson RL. A randomized, double-blind, placebo-controlled trial of oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbations. Presented at 2004 NACFC. Pediatr Pulmonol, supplement 27, abstract 327, 2004.

60. Retsch-Bogart G, Gibson RL for the AI Phase 2 Study Group. A phase 2 study of aztreonam lysinate for inhalation (AI) to treat cystic fibrosis patients with Pseudomonas aeruginosa infections. Presented at the American Thoracic Society, May 2005. Am J Resp Crit Care Med, 2005, Volume 2, Abstract Issue, page A576.

61. Stapleton KW, Gibson RL, Retsch-Bogart G et al. The effect of nominal dose and treatment duration alters the pulmonary deposition of inhaled antibiotics. Presented at the International Society for Aerosol Medicine, 2005.

62. McKone E, Rogers CE, Genatossio A, McNamara S, Gibson RL, Aitken ML. Candidate pathway approach to identifying genetic modifiers in cystic fibrosis. Pediatr Pulmonol, Suppl 28: Abstract 185, pg 252, 2005.

63. McKone EF, Rogers CE, Genatossio A, McNamara S, Gibson RL, Aitken ML. Environmental tobacco smoke exposure and lung function decline in cystic fibrosis. Pediatr Pulmonol, Suppl 28: Abstract 396, pg. 329, 2005.

64. McKone EF, O’Connor CM, Rogers CE, Genatossio A, McNamara S, Gibson RL, Elborn J, Gallagher CG, Kalsheker N, Aitken M. The influence of common genetic variants on the cystic fibrosis phenotype. Presented at the 2006 NACFC. Pediatr Pulmonol, Suppl 29: Abstract 207, p 280, 2006.

65. Rosenfeld M, Emerson J, Uh D, Anderson G, Genatossio A, McNamara S, Dunn C, Davies Z, Foster J, Kantor E, Moss R, Burns J, Aitken M, Gibson RL. Does tobramycin accumulate in respiratory secretions with repeated aerosol administration: a pilot study. Presented at the 2006 NACFC. Pediatr Pulmonol, Suppl 29: Abstract 342, pg 327, 2006.

66. McKone EF, O’Connor CM, Rodgers CE, Genatossio A, McNamara S, Gibson RL, Kalsheker N, Gallagher CG, Aitken M. TAGSNP evaluation of the endothelin pathway demonstrates genetic association between EDNRA and CF lung disease severity. Presented at the 2007 NACFC. Pediatr Pulmonol, Suppl 30, Abstract 202, pg 273, 2007.

67. Retsch-Bogart GZ, Montgomery B, Gibson R, McCoy K, Oermann CM, Cooper P. Phase 3 trial (AIR-CF 1) measuring improvement in respiratory symptoms in patients with cystic fibrosis following treatment with aztreonam lysine fro inhalation. Presented at the 2007 NACFC. Pediatr Pulmonol, Suppl 30, Abstract 308, pg 310, 2007.

68. Burns JL, Worrell K, Kuypers J, McNamara S, Emerson J, Gibson R, Englund JA. PCR diagnosis of respiratory viruses in children with cystic fibrosis. Presented at the 2007 NACFC. Pediatr Pulmonol, Suppl 30, Abstract 315, pg 313, 2007.

69. Rosenfeld M, Gibson R, Emerson J, McNamara S, Escobar DM, Andrina M, Chatfield B, Orenstein DM, Konstan MW, Rock M, Wall M, Ramsey BW. Large US cohort of young, Pseudomonas-negative CF patients: mild lung disease, heterogeneous management. Presented at 2007 NACFC. Pediatr Pulmonol, Suppl 30, Abstract 368, pg 332, 2007.

70. McCoy K, Retsch-Bogart G, Gibson R, Oermann C, Braff M, Montgomery AB. Microbiologic resistance and clinical efficacy of aztreonam lysine for inhalation (AZLI) in cystic fibrosis (CF). Presented at European CF Conference 2008.

71. Sanders DB, Emerson J, Hoffman L, Gibson R, Redding G, Goss CH. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Am J Resp Crit Care Med 177: A774, 2008.

72. Oermann CM, Retsch-Bogart G, McCoy KS, Gibson RL, Montgomery AB. Multiple courses of aztreonam lysine for inhalation to treat Pseudomonas aeruginosa airway infection in patients with cystic fibrosis: 6 month interim analysis of an open-label study. Am J Resp Crit Care Med 177: A460, 2008.

73. Kraynack NC, Chmiel JE, Xue W, Schluchter MD, Gibson RL, Kelley TJ, Hilliard JB, Konstan MW. Effect of simvastatin on exhaled nitric oxide and inflammatory markers in sputum in patients with cystic fibrosis. Pediatr Pulmonol, Supplement 31, Abstract # 281, page 300, 2008.

74. Retsch-Bogart GZ, McCoy KS, Gibson RL, Oermann CM, Braff MH, Montgomery AB. Sustained improvement in pulmonary function following a 28-day course of 75 mg AZLI TID therapy. Pediatr Pulmonol, Supplement 31, Abstract # 335, page 320, 2008.

75. Retsch-Bogart GZ, McCoy KS, Gibson RL, Oermann CM, Montgomery AB. Source of improvements in lung function in patients with CF following treatment with aztreonam lysine for inhalation (AZLI). Pediatr Pulmonol, Supplement 31, Abstract # 336, page 320, 2008.

76. McKoy KS, Retsch-Bogart GZ, Gibson R, Oermann C, Braff MH, Montgomery AB. Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in CF. Pediatr Pulmonol, Supplement 31, Abstract # 418, page 351, 2008.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download